Bitte aktivieren Sie Javascript um alle Funktionen nutzen zu können und ihre Nutzererfahrung zu verbessern.
EHC 2024
Programm
Poster
Suche
DE
Zurück
Poster session
PoS 3
ePoster 01
Termin
Datum:
05.12.
Zeit:
17:00
–
18:30
Ort / Stream:
ePoster station 1
Programm
ePoster
P178
Migraine preventive treatment with eptinezumab improved patient-reported outcomes in patients with non-response on frequency of monthly migraine days
Jessica Ailani (McLean, VA, US)
ePoster
P179
Treatment with Zavegepant offers improvements in pain severity over 48-hours when compared with Placebo – post hoc results from a randomized Placebo-controlled trial (BHV3500-301)
Jessica Cirillo (New York, US)
ePoster
P180
Contemporary prospective understanding of migraine real-world evidence (CAPTURE): baseline patient-reported outcomes
Elizabeth Leroux (Montreal, CA)
Laurent Delahaye (Rungis, FR)
ePoster
P181
Long-term safety and discontinuation for rimegepant versus lasmiditan – a matching-adjusted indirect comparison
Aaron Jenkins (Tadworth, GB)
ePoster
P182
Chronic migraine and ergots use cause higher serum pentraxin 3 levels and endothelial dysfunction in migraine
Mona Nada (Cairo, EG)
ePoster
P183
Impact of Fremanezumab cessation and reinitiation in migraine management: PEARL study 4th interim analysis
Tomáš Nežádal (Prag, CZ)
ePoster
P184
Physical activity levels analysis in patients with chronic migraine treated with Fremanezumab. Phy-My-Mig Study
Álvaro Sierra Mencia (Valladolid, ES)
ePoster
P185
Migraine prevalence: findings from the Americas' Migraine Observatory Study (AMIGOS)
Marco Lisicki (Córdoba, AR)
ePoster
P186
Changes in acute migraine medications use after initiating or switching to a migraine preventive medication: 12-month findings from the observational TRIUMPH study
Maurice Vincent (Rio de Janeiro, BR)
ePoster
P187
Real-world evidence of adding atogepant to OnabotulinumtoxinA for control of chronic migraine – a retrospective chart review
Aubrey Manack Adams (Irvine, US)
ePoster
P188
Real-world treatment patterns of Galcanezumab and traditional oral migraine preventives: 12-month results from the TRIUMPH study
Maurice Vincent (Rio de Janeiro, BR)
ePoster
P189
Real-world evaluation of Eptinezumab in Italy: effectiveness, tolerability, and safety in high-frequency and chronic migraine at 12 weeks – the EMBRACE study
Cinzia Aurilia (Rome, IT)
ePoster
P190
A cross-sectional analysis evaluating the humanistic and economic burden of migraine with comorbid depression using the national health and wellness survey
Hasan Akcicek (Amsterdam, NL)
ePoster
P191
Lasmiditan for migraine. Experience in a headache center in Barcelona
Afra Irene Gilbert (Barcelona, ES)
ePoster
P192
Integrative analysis of omics markers associated with neuronal damage in migraine
Victor Jose Gallardo López (Barcelona, ES)
ePoster
P193
Exploring the link between inhibitory cognitive control and sensory sensitivity in migraine – a case-control study
Nara Ikumi (Barcelona, ES)
ePoster
P194
Manual therapy as a prophylactic treatment for migraine. A randomized controlled trial
Andreas Amons (Amsterdam, NL)
ePoster
P195
Switching between Ligand and receptor anti-CGRP antibodies in non-responders
Nancy van Veelen (Leiden, NL)
v1.20.0
© Conventus Congressmanagement & Marketing GmbH
Impressum
Datenschutz